Clavulanic Acid

CHEMBL777 Phase 4 承認済み Small molecule

Half-Life

—

Bioavailability

—

Protein Binding

—

Molecular Weight

199.2 g/mol

LogP

-1.2

Phase

4

A beta-lactam compound that acts as a suicide inhibitor of bacterial beta-lactamase enzymes by forming an irreversible covalent bond with the enzyme's active site. When combined with susceptible beta-lactam antibiotics such as amoxicillin, it dramatically expands antibacterial coverage to include many resistant organisms. It is not used as a standalone antibiotic due to its weak intrinsic antibacterial activity.

分子量

199.1600 g/mol

LogP

-1.20

TPSA

87.10 Å²

リピンスキーの五則

適合

治療領域

Infectious Disease Bladder Cancer Pain Management Asthma Chronic Obstructive Pulmonary Disease Generalized Anxiety Disorder Chronic Kidney Disease Deep Vein Thrombosis / Pulmonary Embolism Obesity Lymphoma Type 2 Diabetes Chronic Pain Tuberculosis Atrial Fibrillation Prostate Cancer Colorectal Cancer Leukemia

作用機序

Inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), preventing transpeptidation and cross-linking of peptidoglycan chains. This weakens the bacterial cell wall, leading to osmotic lysis and cell death.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

機序

Inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), preventing transpeptidation and cross-linking of peptidoglycan chains. This weakens the bacterial cell wall, leading to osmotic lysis and cell …

2D構造

SVG PNG

Cite this structure

Embed this structure

SMILES

O=C(O)[C@H]1/C(=C/CO)O[C@@H]2CC(=O)N21

InChI

InChI=1S/C8H9NO5/c10-2-1-4-7(8(12)13)9-5(11)3-6(9)14-4/h1,6-7,10H,2-3H2,(H,12,13)/b4-1-/t6-,7-/m1/s1

Molecular Formula

C8H9NO5

HBD / HBA

2 / 5

回転可能結合数

2

重原子数

14

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

よくある質問

A beta-lactam compound that acts as a suicide inhibitor of bacterial beta-lactamase enzymes by forming an irreversible covalent bond with the enzyme's active site. When combined with susceptible beta-lactam antibiotics such as amoxicillin, it dramatically expands antibacterial coverage to include many resistant organisms. It is not used as a standalone antibiotic due to its weak intrinsic antibacterial activity.

Inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), preventing transpeptidation and cross-linking of peptidoglycan chains. This weakens the bacterial cell wall, leading to osmotic lysis and cell death.

Yes, Clavulanic Acid is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

ChEMBL — European Bioinformatics Institute (EBI). CHEMBL777. Open-access bioactivity database.
PubChem — National Center for Biotechnology Information (NCBI). CID 5280980. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.

PillFYI

患者向けのわかりやすい情報をお探しですか？

Clavulanic Acid PillFYIで

構造

クイックデータ

分子式: C8H9NO5

外部リンク

Cite

BibTeX, APA, MLA, Chicago, IEEE, Harvard

医学的免責事項

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.